- Jiang, Yuanbing;
- Zhou, Xiaopu;
- Wong, Hiu Yi;
- Ouyang, Li;
- Ip, Fanny CF;
- Chau, Vicky MN;
- Lau, Shun-Fat;
- Wu, Wei;
- Wong, Daniel YK;
- Seo, Heukjin;
- Fu, Wing-Yu;
- Lai, Nicole CH;
- Chen, Yuewen;
- Chen, Yu;
- Tong, Estella PS;
- Alzheimer’s Disease Neuroimaging Initiative;
- Mok, Vincent CT;
- Kwok, Timothy CY;
- Mok, Kin Y;
- Shoai, Maryam;
- Lehallier, Benoit;
- Losada, Patricia Morán;
- O'Brien, Eleanor;
- Porter, Tenielle;
- Laws, Simon M;
- Hardy, John;
- Wyss-Coray, Tony;
- Masters, Colin L;
- Fu, Amy KY;
- Ip, Nancy Y
Changes in the levels of circulating proteins are associated with Alzheimer's disease (AD), whereas their pathogenic roles in AD are unclear. Here, we identified soluble ST2 (sST2), a decoy receptor of interleukin-33-ST2 signaling, as a new disease-causing factor in AD. Increased circulating sST2 level is associated with more severe pathological changes in female individuals with AD. Genome-wide association analysis and CRISPR-Cas9 genome editing identified rs1921622 , a genetic variant in an enhancer element of IL1RL1, which downregulates gene and protein levels of sST2. Mendelian randomization analysis using genetic variants, including rs1921622 , demonstrated that decreased sST2 levels lower AD risk and related endophenotypes in females carrying the Apolipoprotein E (APOE)-ε4 genotype; the association is stronger in Chinese than in European-descent populations. Human and mouse transcriptome and immunohistochemical studies showed that rs1921622 /sST2 regulates amyloid-beta (Aβ) pathology through the modulation of microglial activation and Aβ clearance. These findings demonstrate how sST2 level is modulated by a genetic variation and plays a disease-causing role in females with AD.